Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8 Ubunyulu > 98.0% (GC) Lenvatinib Mesylate Intermediate Factory

Inkcazelo emfutshane:

Igama leKhemikhali: Methyl 4-Amino-2-Methoxybenzoate

CAS: 27492-84-8

Ubunyulu: >98.0% (GC)

Imbonakalo: Imhlophe ukuya kwiPowder eNgaphandle-Mhlophe okanye iiCrystals

Umbindi weLenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

Iipropati zeMichiza:

Igama leMchiza I-Methyl 4-Amino-2-Methoxybenzoate
Izithethantonye 4-Amino-2-Methoxybenzoic Acid Methyl Ester;I-Methyl 4-Amino-o-Anisate;4-Amino-o-Anisic Acid Methyl Ester
Inombolo yeCAS 27492-84-8
Inombolo yeCAT RF-PI1974
Ubume beStokhwe Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni
Ifomula yeemolekyuli C9H11NO3
Ubunzima beMolekyuli 181.19
Ukuxinana 1.179±0.060 g/cm3
Uphawu Ruifu Chemical

Iinkcukacha:

Into Iinkcukacha
Imbonakalo Mhlophe ukuya kwiPowder eNgaphandle-Mhlophe okanye iiCrystals
Ubunyulu / Indlela yokuHlalutya >98.0% (GC)
Ubunyulu / Indlela yokuHlalutya 97.5 ~ 102.5 (Nonaqueous Titration)
Indawo yokunyibilika 157.0 ~ 161.0℃
Ilahleko ekomisweni <1.00%
Ukungcola ngokupheleleyo <2.0%
I-Infrared Spectrum Iyahambelana noLwakhiwo
Proton NMR Spectrum Iyahambelana noLwakhiwo
Umgangatho woVavanyo Umgangatho woShishino
Ukusetyenziswa Umbindi weLenvatinib Mesylate (CAS: 857890-39-2)

Ukupakishwa kunye noGcino:

Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma

Izinto eziluncedo:

1

FAQ:

Isicelo:

I-Methyl 4-Amino-2-Methoxybenzoate (i-CAS: 27492-84-8) ingasetyenziselwa njengendawo ephakathi yeLenvatinib Mesylate (CAS: 857890-39-2).I-Lenvatinib isilwanyana somhlaza we-thyroid esakhiwe yi-Eisai Corporation yaseJapan (iKhowudi: E7080), eyingxenye ye-inhibitor ye-oral multi-receptor tyrosine kinase (RTK) kwaye inokuthintela umsebenzi we-kinase we-vascular endothelial growth factor (VEGF) i-Receptors VEGFR1 ( FLT1), VEGFR2 (KDR), kunye neVEGFR3 (FLT4).I-Lenvatinib inokuthintela ukubandakanyeka kwezinye ii-RTKs kwi-angiogenesis ye-pathological, ukukhula kwe-tumor, kunye nokuqhubela phambili komhlaza ngaphandle kwemisebenzi yabo eqhelekileyo yeselula kubandakanya i-fibroblast growth factor (FGF) receptors FGFR1, 2, 3, kunye ne-4;I-Platelet-derived growth factor receptor (PDGFR [alpha]), i-KIT, kunye ne-RET.[Izibonakaliso]: I-Lenvatinib ifanelekile kunyango lwezigulane zomhlaza we-thyroid wokuphindaphinda kwendawo okanye uhlobo lwe-metastasis, uhlobo lwe-progressivity kunye ne-radioactive iodine-refractory differentiated type.Ngomhla we-13 kaFebruwari, i-2015, i-US FDA ivume i-anticancer drug Lenvatinib kunyango lomhlaza we-thyroid.I-Lenvatinib yi-inhibitor ye-enzyme ejoliswe kwizinto ezininzi, ekwazi ukuthintela i-VEGFR2 kunye ne-VEGFR3 (i-vascular endothelial growth factor receptor).Igama lezorhwebo leLenvatinib yiLenvima.Ngomhla we-20 kaMeyi, i-2015, i-Arhente yeMithi yaseYurophu (EMA) ivume i-Lenvatinib yonyango lwe-invasive, indawo ehamba phambili okanye i-metastatic differentiated (i-papillary, i-follicular, uhlobo lwe-Hurthle) umhlaza we-thyroid (DTC).Kulingo, ixesha eliphakathi lokusinda kwizigulane ze-DTC ene-radioactive iodine-refractory enyangwa nge-Lenvatinib yayiziinyanga ezili-18 ngelixa ixabiso lezigulane ezithatha indawo ye-placebo ziinyanga ezi-3 kuphela.

Bhala umyalezo wakho apha kwaye uwuthumele kuthi